Goat's Rue (Galega officinalis L.): A Comprehensive Reference
1. Identity: Botanical Classification, Names, and Forms
Taxonomy and Nomenclature
Galega officinalis, commonly known as galega or goat's rue, is a herbaceous plant in the subfamily Faboideae of the legume family Fabaceae. Its full scientific classification places it in Kingdom Plantae, Order Fabales, Family Fabaceae (Leguminosae), Subfamily Faboideae (Papilionoideae), Tribe Galegeae, Genus Galega, Species Galega officinalis. The plant carries numerous common names in different languages and traditions: it is often called galega, French lilac, Italian fitch, or professor weed. Some additional regional names include Pestilenzkraut, reflecting its diverse uses and cultural significance across different regions.
The etymology of both the common and genus names reflects the plant's most celebrated traditional use. The plant is named Goat's Rue after the disagreeable odor released upon bruising; the genus name Galega is derived from gala, meaning milk, and ago, meaning to bring on. The English name "goat's-rue" is a translation of the Latin Ruta capraria.
Botanical Description and Natural Distribution
The plant is native to parts of northern Africa, western Asia, and Europe, but is widely cultivated and naturalised elsewhere. It is a perennial herb with summer blossoms that grows abundantly in grasslands, swamps, and along riverbanks. Goat's rue is an herbaceous perennial, growing up to 1.2 meters by 75 cm wide. This vigorous, bushy plant has bright green compound leaves, each with 13–17 lance-shaped leaflets approximately 2–5 cm long. The white to pink-lilac flowers give way to seed pods which hold 2–6 kidney-shaped seeds. The erect, branching stems are smooth and hollowed and support the long floral stalks.
In 1891 in the United States, Galega officinalis was introduced experimentally at Utah State University for potential use as a forage crop, but escaped cultivation and is now an agricultural pest. As a result, it has been placed on the Federal Noxious Weed List in the United States. The plant has been extensively cultivated as a forage crop, an ornamental, a bee plant, and as green manure.
Parts Used and Common Preparations
Goat's rue leaves and flowering tops contain numerous guanidine derivatives, including galegine. The aerial parts — leaves and flowering tops — are used to make teas, tinctures, and standardized capsules. The plant's aboveground parts (herba) are harvested and processed into aqueous-alcoholic extracts containing guanidine alkaloids, particularly galegine. It is mucilaginous and has a bitter and astringent taste.
2. Traditional and Historical Use
Ancient and Medieval European Use
Goat's rue has a long history of use as a diuretic and has been described as a plant with significant therapeutic efficacy. In addition to its purported effect to lower blood glucose levels and induce diuresis, goat's rue was used as a herbal tonic in folk medicine practices of medieval Europe to treat bubonic plague, worms, and snake bites. Used by herbalists since the Middle Ages for treating symptoms of diabetes, investigations into the blood-glucose lowering effects of goat's rue in the 1920s led to the development of metformin.
The history of metformin can be linked to the herbal use of Galega officinalis (goat's rue or French lilac), which was described in the 1700s as a traditional treatment for thirst and frequent urination. It is believed to have been used as a diuretic and tonic for typhoid conditions and as a nervous system stimulant. Goat's rue has been used as a soak for tired feet and as an herb in cheese making. Hill's Universal Herbal (1832) mentions the addition of the dried flowers to boiling water to make an infusion for drinking to induce sweating and reduce fever.
In medieval European traditional medicine, goat's rue was employed for diverse conditions including plague, snake bites, diabetes, digestive issues, tuberculosis, and rheumatic pain.
Traditional Use in Lactation Support
Goat's rue has been traditionally relied upon for centuries due to its galactogogue properties, especially in Europe and parts of Asia. This herb's historical use dates back to ancient times when women sought natural remedies to enhance milk production. In the Middle Ages, goat's rue was a common component in herbal remedies prescribed by midwives and herbalists. Its role in enhancing milk supply was documented in various texts, underlining the importance of natural solutions for postpartum women.
The genus name Galega is derived from 'gale' meaning milk and 'ega' meaning 'to bring on'. This is a reference to the use of goat's rue to encourage the milk flow of small animals, such as goats. This value was first noted by farmer Gillet Daimitte in a letter to the French Academy in 1873. The letter contained details of a 35–50% increase in milk yield after feeding goat's rue to dairy animals.
It has been used as a galactogogue in domestic animals since ancient times, and at the beginning of the 20th century it was seen to increase milk production in cows.
Use in Traditional Antidiabetic Practice
Galega officinalis is a leguminous plant whose aerial parts have long been used in traditional and folk medicine to treat diabetes in Chile, Japan as well as Europe. The modern drug metformin (a biguanide) is a derivative of an active natural product, galegine, a guanidine isolated from the plant Galega officinalis L., which was used in the medieval times to relieve the intense urination in diabetic people.
3. Key Constituents and Active Compounds
Primary Nitrogen-Containing Alkaloids
Although not thoroughly studied with 21st-century methods, G. officinalis has been analyzed for its constituents, which include galegine, hydroxygalegine, several guanidine derivatives such as 4-hydroxygalegine, flavones, flavone glycosides, kaempferol, and quercetin.
Galega officinalis contains the active phytochemical galegine, also known as 2-(3-methylbut-2-enyl)guanidine, with the molecular formula C₆H₁₃N₃. Structurally, galegine is a guanidine derivative with an alkyl side chain attached to the guanidine functional group. Its structure can be described by the IUPAC name 2-(3-methylbut-2-enyl)guanidine, indicating it has a 3-methylbut-2-enyl group attached to the nitrogen of guanidine.
The herb consists of two nitrogen guanidine constituents: galegin (synonymous with galegine) as isoamylene guanidine and hydroxygalegine, prevalent in all parts during flowering and forming of fruits. These bioactive substances possess pharmacological features as hypoglycemic and galactogenic factors. Galegin has been reported to decrease blood pressure and to paralyze the CNS.
Polyphenolic and Flavonoid Constituents
G. officinalis also consists of some critical secondary metabolites such as medicarpin, sativan, flavonol triglycosides, kaempferol, and quercetin, and also it consists of fatty acids, glycosides, phenols, resins, terpenes, and steroids. Research has confirmed the presence of tricyclic quinazoline alkaloids, guanidines, flavonoids, and hydroxycinnamic acids (HCAs) in galega extracts. The polyphenolic fraction is dominated by mono-, di-, and triglycosylated flavonols, as well as monocaffeoylhexaric acids.
Research indicates that Galega officinalis contains flavonoids, phenolic compounds, and triterpenes, which enhance its antioxidant activity.
Other Constituents
Its tannins, terpenoids, alkaloids, flavonoids, phenols, and other compounds have shown antidiabetic potential. The plant is mucilaginous and has a bitter and astringent taste, consistent with the presence of tannins and saponins noted in phytochemical surveys.
4. Established Mechanisms of Action
Galegine and the Guanidine–Biguanide Connection
Chemically, galegine is an isoprenyl derivative of guanidine, while metformin and phenformin are biguanides containing two coupled molecules of guanidine with additional substitutions. Galegine can be considered a simpler guanidine derivative found naturally in Galega officinalis, while metformin is a more complex biguanide synthetic molecule inspired by the guanidine-containing compounds of the plant's extract. The common feature is the guanidine moiety, which is crucial for the hypoglycemic activity.
AMPK Activation and Glucose Metabolism
The weight-reducing effects of galegine had not previously been studied, and a 2008 investigation was undertaken to determine its mechanism(s) of action. Using cell lines and mouse models, the study found that galegine at 10 mM and above produced a concentration-dependent activation of AMP-activated protein kinase (AMPK) in H4IIE rat hepatoma cells, HEK293 human kidney cells, 3T3-L1 adipocytes, and L6 myotubes. Activation of AMPK can explain many of the effects of galegine, including enhanced glucose uptake and inhibition of acetyl-CoA carboxylase. Inhibition of acetyl-CoA carboxylase both inhibits fatty acid synthesis and stimulates fatty acid oxidation, and this may contribute to the in vivo effect of galegine on body weight.
In 3T3-L1 adipocytes and L6 myotubes, galegine (50 μM–3 mM) stimulated glucose uptake. Activation of AMPK can explain many of the effects of galegine, including enhanced glucose uptake and inhibition of acetyl-CoA carboxylase. Inhibition of acetyl-CoA carboxylase both inhibits fatty acid synthesis and stimulates fatty acid oxidation, and this may contribute to the in vivo effect of galegine on body weight.
Inhibition of Intestinal Glucose Transport
Research referenced in pharmacological databases identified an in vitro study demonstrating inhibitory effects of Galega officinalis on glucose transport across monolayers of human intestinal epithelial cells (Caco-2). This mechanism — reducing the rate of glucose absorption from the intestine — parallels one of the proposed actions of metformin and suggests a complementary pathway through which the whole herb may exert hypoglycemic effects.
Non-Alkaloid Hypoglycemic Fraction
The hypoglycemic potential of G. officinalis was established in 1927, but the literature on the sugar-lowering effect of herbs and seeds of this species is contradictory. It was previously thought that the hypoglycemic action is inherent in alkaloids. More recent work has challenged this: it was found that even the non-alkaloid extract has a hypoglycemic effect and is potentially non-toxic. New analyses showed that other phytochemical compounds, such as polyphenols, have hypoglycemic effects.
Antioxidant Mechanisms
In vitro tests indicated which G. officinalis components exhibit beneficial antioxidative and methylglyoxal (MGO) trapping effects. For galega extracts, flavonols, and hydroxycinnamic acids, a potent antiradical activity was observed. The ability to trap methylglyoxal — a reactive carbonyl compound implicated in diabetic complications — was noted for guanidines and flavonoids, whereas hydroxycinnamic acid esters and quinazoline alkaloids were ineffective. The formation of mono-MGO adducts of galegine, hydroxygalegine, and rutin in a water infusion was observed.
Immunomodulatory Effects in Experimental Diabetes
Under diabetes mellitus, the administration of Galega officinalis promotes restoration of leukocyte precursors' bone marrow pool and normalizes their proliferative activity. This plant protects the functional state of leukocytes by modulating actin cytoskeleton formation and through quantitative redistribution of leukocyte membrane glycoconjugates. Galega officinalis prevents the development of diabetes-associated oxidative stress, which results in antiapoptotic activity. The normalization of leukocytes' proliferative and functional capacity, along with its antiapoptotic and hypoglycemic effects, may improve the course of the disease and prevent the development of diabetic complications. These findings, however, derive from animal model studies and have not been confirmed in human trials.
5. The Galegine–Metformin Historical Connection
The most scientifically significant aspect of Galega officinalis is its foundational role in the development of one of the world's most widely prescribed drugs. Its history is linked to Galega officinalis (also known as goat's rue), a traditional herbal medicine in Europe, found to be rich in guanidine, which, in 1918, was shown to lower blood glucose.
The primary active anti-diabetic chemical in the extracts from French Lilac is the alkaloid galegine (isoamylene guanidine); however, galegine is too toxic for chronic use, and in the late 19th century German chemists Adolph Strecker and Bernhard Rathke synthesized guanidine and biguanides.
Galegine was tested as a glucose-lowering agent in humans in the 1920s but was found to be too toxic. At about the same time, two synthetic derivatives of galegine, metformin and phenformin, were first synthesised and tested, although they were not introduced to clinical use until the 1950s.
Galegine was isolated by French pharmacist Georges Tanret in 1914. Although galegine was used with success, it was quickly abandoned because of its toxicity. In the 1920s, biguanides were produced, containing two guanidine molecules linked by an alkyl chain of varying lengths. Guanidine derivatives, including metformin, were synthesised and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin.
Metformin was rediscovered in the search for antimalarial agents in the 1940s and, during clinical tests, proved useful to treat influenza when it sometimes lowered blood glucose. This property was pursued by the French physician Jean Sterne, who first reported the use of metformin to treat diabetes in 1957.
Once used in traditional medicine over centuries, G. officinalis is at the foundation of the biguanide class of antidiabetic drugs, which also included phenformin and buformin (both discontinued). Sixty years after its introduction in diabetes treatment, metformin has become the most prescribed glucose-lowering medicine worldwide.
6. Scientific Evidence by Area of Use
6.1 Blood Glucose Regulation and Antidiabetic Effects
Evidence strength: Preclinical (animal and in vitro) only; no published human RCTs for whole-herb preparations.
As potential sources of biologically active substances with antidiabetic action, a pronounced hypoglycemic effect of Galega officinalis extract, devoid of alkaloids, at a dose of 600 mg/kg in experimental diabetes mellitus has been demonstrated in animals. The established effect is evidenced by a decrease in the concentration of glucose and glycosylated hemoglobin in the blood, increased glucose tolerance of cells, and increased C-peptide and insulin content in the plasma of rats' blood.
The effective hypoglycemic effect of the extract in the studied pathology was confirmed by histological examination of the pancreas. A cytoprotective effect of the studied extract on pancreatic cells was experimentally confirmed at a dose of 1200 mg/kg.
An acetone-water extract of G. officinalis exhibited the highest inhibition of sucrase activity (91.42%). Also, the inhibitory activity against α-amylase (59.96%), α-glucosidase (54.3%), and maltase (62.73%) was significantly higher for this extract. These enzyme inhibition results are in vitro findings only and do not establish clinical glucose-lowering efficacy in humans.
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on Galega officinalis. All available evidence is limited to preclinical animal studies in diabetic mice and rats, and in vitro laboratory investigations. Human safety and efficacy remain unestablished through clinical research.
Goat's rue was denied approval by the German Commission E for its use in the treatment of diabetes, as a diuretic, or as a galactogogue, due to a considered lack of evidence regarding its effectiveness.
6.2 Lactation Support (Galactogogue)
Evidence strength: Weak; human studies methodologically limited; no trials isolating goat's rue alone.
Goat's rue is widely used internationally as a galactogogue. No scientifically valid clinical trials support this use, although some old, poorly controlled studies found an effect. Although it has a long history of use as a galactogogue, very limited scientific data exist on the safety and efficacy of goat's rue in nursing mothers or infants.
The few studies that claim to demonstrate its galactogogue properties (Serrao 2018, Ozalkaya 2018, Zecca 2016, Turkyilmaz 2011) use a mixture of herbs, all allegedly galactogogues, in mothers from the test group, so that the effect found cannot be attributed to one herb in particular.
A survey was conducted on 238 mothers in Italy who were using a commercial goat's rue supplement that also contained vitamins and magnesium (Lactogal Plus, Loacker-Remedia, Italy) as a galactogogue. Sixty-seven percent of mothers felt there was an increase in milk production, and 88% felt that the product had benefited the breastfeeding experience. This survey relied on self-reported outcomes from a multi-ingredient product, limiting conclusions about goat's rue per se.
A standardized food supplement used to support breastfeeding mothers containing Galega officinalis and other substances, including vitamins and magnesium, was evaluated in a large sample of Italian women. The wide majority of mothers declared satisfaction with the product, and two-thirds reported improved milk production. This galega-based food supplement was also reported to promote psychological benefit.
Although other herbs were identified as commonly used to induce or augment lactation, such as Galega officinalis (goat's rue), no peer-reviewed publications on these herbal preparations were identified that met inclusion criteria in a systematic review searching PubMed and EMBASE up to 2015.
Goat's rue is widely used as a galactogogue in Europe based on the observation that it increased milk supply in cattle in the early 1900s. No human trials for effectiveness have been done; however, limited animal studies have shown a milk supply increase of up to 50%.
Its lactogenic value has to be considered according to reported increases in milk yield and lactation persistency when included in a daily diet in cows and sheep. Genus Galega is considered to be of low palatability and high toxicity, due to high concentrations of guanidine-derived molecules hydroxygalegine and galegine. The toxic effects of G. officinalis in sheep may vary among individuals, but in all cases, doses over 5 g/kg are toxic.
6.3 Body Weight and Anti-Obesity Effects
Evidence strength: Preclinical (animal and in vitro) only; no human studies.
Galegine administered in the diet reduced body weight in mice. Pair-feeding indicated that at least part of this effect was independent of reduced food intake. Additional rodent studies demonstrated that 10% w/w galega in diet reduced body weight, food intake, and fat mass.
The mechanism was elucidated in the same 2008 British Journal of Pharmacology study: activation of AMPK can explain many of the effects of galegine, including enhanced glucose uptake and inhibition of acetyl-CoA carboxylase. Inhibition of acetyl-CoA carboxylase both inhibits fatty acid synthesis and stimulates fatty acid oxidation. No human trials have extended these findings to clinical populations.
6.4 Antioxidant Activity
Evidence strength: In vitro only.
Hot water and aqueous methanol extracts were assessed for antioxidant activity using DPPH and ABTS assays. For galega extracts, flavonols, and hydroxycinnamic acids, a potent antiradical activity was observed. The ability to trap methylglyoxal was noted for guanidines and flavonoids, whereas hydroxycinnamic acid esters and quinazoline alkaloids were ineffective. Antioxidants in G. officinalis may protect against renal diseases and complications from diabetes mellitus, although this suggestion is based on preclinical and in vitro evidence only.
6.5 Antibacterial and Antiplatelet Activity
Evidence strength: Preclinical (in vitro and animal) only.
Various studies on G. officinalis have investigated antibacterial properties, though these remain at the laboratory level. Because of its ability to inhibit platelet aggregation, there may be an increased risk of bleeding and bruising with administration of goat's rue. This antiplatelet finding derives from animal (rat) studies.
6.6 Diuretic Use
Evidence strength: Traditional use only; no clinical evidence.
In ancient herbalism, goat's rue was used as a diuretic. Goat's rue, traditionally used as a diuretic and tonic, has more recently been found to be effective at relieving the symptoms associated with diabetes. The German Commission E did not approve it for this indication, citing lack of evidence.
7. Body Systems and Health Areas of Association
- Endocrine / Metabolic system: Galega officinalis has remarkable potential to be an antidiabetic plant to control type 2 diabetes, as both polyphenols and galegine can play a vital role in decreasing fasting blood glucose level — demonstrated to date only in preclinical settings.
- Reproductive system / Lactation: Goat's rue is widely used internationally as a galactogogue, with use documented across European herbal traditions.
- Cardiovascular / Platelet function: Preclinical evidence of antiplatelet action has been documented in rat studies, raising interaction concerns with anticoagulant drugs.
- Immune system: Galega, goat's rue, French lilac, is a promising plant that can be used for treatment of a wide range of inflammatory diseases, including diabetes mellitus — based on animal model data.
- Urinary system: Historical use as a diuretic is recorded across multiple European traditions, though without clinical validation.
- Digestive system: It was used traditionally as a diaphoretic and galactagogue and is described in traditional sources as a digestive tonic.
8. Dosage Forms and Dosages Reported in Sources
No clinically studied human dosages exist. Animal studies used 50 mg/kg optimized leaf extract intraperitoneally or 10% w/w galega herb in the diet. A historical therapeutic dose has been recommended as 4 g/day dried herb.
A pronounced hypoglycemic effect of Galega officinalis extract, devoid of alkaloids, was demonstrated at a dose of 600 mg/kg in experimental (rat) diabetes mellitus. The cytoprotective effect of the studied extract on pancreatic cells at a dose of 1200 mg/kg was experimentally confirmed — both in rodent models only.
A study by Mooney et al. reported that no toxic effects of galegine were observed in rats at a dose of 600 mg per kilogram body weight for over 28 days.
The modern clinical evidence base for whole-herb Galega in diabetes or lactation is limited. Long-standing traditional use exists, but robust randomized trials are sparse, small, or methodologically weak. There is no accepted consumer-facing standard for galegine or other bioactives in finished products.
Regarding dosage forms used in lactation studies, sixty-six subjects were enrolled and randomized 1:1:1 into treatment, placebo, and control arms, with mothers in the treatment group (n = 22) instructed to consume daily a minimum of 3 cups of a commercially available herbal tea containing fenugreek and other herbs including goat's rue — reflecting the typical multi-herb formulation used in most published studies.
9. Safety Considerations and Drug Interactions
Toxicity Profile
G. officinalis has demonstrated toxicity; caution is warranted in its use despite its therapeutic potential. Toxic effects of goat's rue have been reported, with most data derived from studies in sheep. Dyspnea, anoxia, and foaming nasal discharge were observed in ewes ingesting doses as small as 0.8 g/kg/day.
This toxicity is due to alkaloids, mainly galegine, and derivatives. Notably, galegine is associated with the toxicity of the plant, but not with the lactogenic potential.
The plant can be poisonous to mammals. In humans, toxicity has been observed with other guanidine derivatives. Most biguanidine preparations developed in the 1950s have been withdrawn from the market. Goat's rue should be used to treat diabetes only under physician supervision due to uncertainty regarding its safety and effectiveness.
Hypoglycemia Risk and Drug Interactions
The plant can cause hypoglycemia, especially when combined with diabetes medications like metformin, insulin, or sulfonylureas. Goat's rue can lower blood glucose and may potentiate medications that do the same. This is the core safety concern for real-world users.
Although not well studied in humans, goat's rue may interact with medicines taken to reduce blood sugar or reduce the risk of bleeding.
Documented Human and Infant Adverse Events
Two newborns and their mothers were seriously intoxicated after the latter drank an average of two litres a day of an infusion mixed with licorice, fennel, anise, and galega. This case report (Rosti et al., 1994, Acta Paediatrica) underlines the risk of excessive consumption of multi-herb infusions containing goat's rue during the postpartum period.
Headache, jitteriness, or weakness may occur. Because of its ability to inhibit platelet aggregation, there may be an increased risk of bleeding and bruising with administration of goat's rue.
Pregnancy
Information regarding safety and efficacy in pregnancy is lacking. Galega is contraindicated during pregnancy due to potential teratogenic effects. This reflects the precautionary position in the absence of human safety data.
Legume Allergy Cross-Reactivity
Galega is a legume family plant. If an individual has known allergies to legumes, they should proceed cautiously.
Regulatory Status
Goat's rue was denied approval by the German Commission E for its use in the treatment of diabetes, as a diuretic or galactogogue, due to a considered lack of evidence regarding its effectiveness. The British Medical Herbal Association recommends it for diabetes mellitus in the UK and Bulgaria, and it has been traditionally employed as a galactogogue to enhance milk production during lactation. These divergent regulatory positions reflect the ongoing disagreement between traditional herbal practice communities and formal evidence-based regulatory bodies.
References
Go back